Wave Life Sciences (WVE) Emerges as Obesity Treatment Contender, Oppenheimer Boosts Price Target

2 hours ago 2

Sheryar Siddiq

Fri, January 2, 2026 astatine 9:50 AM CST 2 min read

Wave Life Sciences Ltd. (NASDAQ:WVE) ranks among the best stocks nether $25 to bargain now. On December 16, Oppenheimer boosted its terms people for Wave Life Sciences Ltd. (NASDAQ:WVE) to $32 from $24, maintaining an Outperform standing connected the company’s shares. The steadfast reported “highly encouraging” interim results for WVE-007, emphasizing the treatment’s cleanable hazard illustration astatine doses up to 600mg and evident easiness of translation from quality genetics and preclinical probe to objective outcomes.

According to Wave Life Sciences Ltd. (NASDAQ:WVE), the medication, erstwhile taken for 3 months, resulted successful a 4.5% full abdominous loss, a 9.4% visceral abdominous reduction, and a 3.2% summation successful thin mass. Wave Life Sciences Ltd (NASDAQ:WVE) stated it plans to merchandise the results of the 2nd circular of the objective trial, which volition span six months for the 240 mg single-dose cohort and 3 months for the 400 mg single-dose cohort.

Beyond its contiguous applications, Oppenheimer sees WVE-007 arsenic a imaginable halfway therapy for not lone obesity but besides different cardiometabolic diseases.

Wave Life Sciences Ltd. (NASDAQ:WVE) is simply a clinical-stage biotech institution that develops and commercializes ribonucleic acerb (RNA) medicines with the assistance of its proprietary PRISM find and cause improvement platform.

While we admit the imaginable of WVE arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This nonfiction is primitively published at Insider Monkey.